Supplemental Figure 5.

Mean A) PANSS Total Scores; and B) CGI-S Scores (Double-blind and Open-label Studies).

\* Least-squares mean difference *P*<0.05 RBP-7000 90 mg versus placebo.

† Least-squares mean difference *P*<0.05 RBP-7000 120 mg versus placebo.

End of Study assessments were performed for all participants 28 days after completion of the last open-label treatment visit (Day 309 for rollover participants, Day 365 for de novo participants). Double-blind assessments performed in intention-to-treat population. Open-label assessments performed in safety population. Scores are observational with no imputation of missing data.

BL, Baseline; CGI-S, Clinical Global Impression-Severity; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation.

